248 filings
Page 2 of 13
8-K
66u0px f3arj0wquf
3 Nov 22
Regulation FD Disclosure
7:32am
8-K
t5z9u33
17 Aug 22
Submission of Matters to a Vote of Security Holders
4:15pm
8-K
7nb96qmnefn tlbvsf2z
11 Aug 22
Abeona Therapeutics Reports Second Quarter 2022 Financial Results
7:30am
8-K
2766kpt5q
20 Jul 22
Other Events
7:30am
8-K
a969 au9b5s
30 Jun 22
Material Modifications to Rights of Security Holders
5:00pm
8-K
c8v58mntrn
14 Jun 22
Submission of Matters to a Vote of Security Holders
5:05pm
8-K
trin4xfcex2p3gp1
19 May 22
Abeona Therapeutics Granted Second 180-Day Period by Nasdaq to Regain Compliance with Minimum Bid Price Rule
7:35am
8-K
ioxd9kae 50mvme0og
17 May 22
Ultragenyx Acquires Global Rights to AAV Gene Therapy ABO-102 for Sanfilippo Syndrome Type A (MPS IIIA) from Abeona Therapeutics
8:01am
8-K
k5h4z6
13 May 22
Abeona Therapeutics Reports First Quarter 2022 Financial Results
7:30am
8-K
qozfa menprq1gvl
2 May 22
Abeona Therapeutics Announces Pricing of $25 Million Private Placement of Convertible Redeemable Preferred Stock
5:14pm
8-K
1i3eeko6
29 Apr 22
Amendments to Articles of Incorporation or Bylaws
12:00am
8-K
t9lo1 3qnzay
31 Mar 22
Abeona Therapeutics Announces Strategy Update and 2021 Financial Results
7:42am
8-K
cbgyjy0
9 Mar 22
Departure of Directors or Certain Officers
4:05pm
8-K
agy7l30kd3e 3f
17 Dec 21
Abeona Therapeutics Announces Pricing of Public Offering of Common Stock and Warrants
5:22pm
8-K
pfg7kw8pzfpx
16 Dec 21
Abeona Therapeutics Announces Public Offering of Common Stock and Warrants
4:42pm
8-K
ksesh5
19 Nov 21
Entry into a Material Definitive Agreement
4:54pm
8-K
7glyv8c5kga
15 Nov 21
Abeona Therapeutics Reports Third Quarter Financial Results
4:07pm
8-K
fcq9o4ri9 kdj
15 Nov 21
Entry into a Material Definitive Agreement
7:30am
8-K
fq9yb0ga73g wojld
21 Sep 21
Abeona Announces New Chairman, Executive Leadership Promotions and Key Talent Additions for Final Push Towards Two Biologics License
4:30pm
8-K
pcfu 0v9ryp
13 Aug 21
Departure of Directors or Certain Officers
5:19pm